全基因组的CRISPR-Cas9淘汰屏幕识别了DNMT1作为声波刺脑膜母细胞瘤中可服用药物的依赖性
Foteini Tsiami1,2, Chiara Lago3, Noemi Pozza3
1Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.
Acta neuropathologica communications
|August 6, 2024
概括
向DNA甲基转移酶1 (DNMT1) 为Sonic hedgehog medulloblastoma (SHH-MB) 提供了一个新的治疗策略. 单独或与SMO抑制剂一起抑制DNMT1,有效地治疗SHH-MB模型并克服耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 声波刺髓母细胞瘤 (SHH-MB) 依赖于SHH信号通路.
- 滑化 (SMO) 抑制剂显示出临床前景,但面临着耐药性挑战.
- 了解耐药机制对于开发新的SHH-MB疗法至关重要.
研究的目的:
- 通过探索遗传依赖来确定SHH-MB的新型治疗点.
- 调查表观遗传调节剂在SHH-MB生长和耐药性的作用.
- 评估DNMT1抑制作为SHH-MB的潜在治疗策略.
主要方法:
- 在小鼠SMB21和人类DAOY细胞中进行了全基因 CRISPR-Cas9 淘汰屏幕.
- 评估了DNA甲基转移酶1 (DNMT1) 在小脑发育和SHH-MB生长中的作用.
- 单独或与SMO抑制剂结合,对DNMT1的药理抑制在临床前模型中进行了测试.
主要成果:
- 在CRISPR屏幕中,DNMT1被确定为SHH-MB的可药物标.
- 在体内,Dnmt1对于正常小脑发育和SHH-MB瘤生长至关重要.
- 在SHH-MB模型中,DNMT1抑制,有或没有SMO抑制,抑制瘤生长和延长存活时间.
结论:
- DNMT1是SHH-MB的关键调节者,也是一个有前途的治疗标.
- 抑制DNMT1代表了对SMO抑制剂敏感和耐药SHH-MB的新策略.
- 准表观遗传调节器为治疗SHH-MB提供了一个新的途径.
相关概念视频
In-vitro Mutagenesis
13.9K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
13.9K
Hedgehog Signaling Pathway
7.3K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.3K


